Effect of valsartan-eluting stents on the expression of angiotensin Ⅱ type 2 receptor

Percutaneous coronary intervention （PCI） with drug-eluting stent implantation has been provedefficient to reduce complications and restenosis in type B2/C lesions compared with bare stent, since the major drawback of the latter technique is intimal hyperplasia from the vessel media, which significantly cause in-stent restonosis. Despite the beneficial effects on the renin-angiotensin-aldosterone （RAAS） system, the role of angiotensin-converting enzyme （ACE） inhibitors after PCI is still unclear. However, first results of angiotensin receptor antagonist （valsartan） after stent implantation in the VaI-PREST1 and VALVACE2 trials have indicated the systemic pharmacological effect in the prevention of in-stent-restenosis. Up to our knowledge, whether local treatment of valsartan by implanting drug-eluting stent can generally prevent restenosis by inhibiting intimal hyperplasia has not been explored.